Merck chief concerned over future U.S. biopharma innovation

Merck ($MRK) CEO Kenneth Frazier has weighed in on some of the U.S. biopharmaceutical industry's most pressing issues in an opinion piece in the Wall Street Journal. He warns that weak protections on drug patents, drug pricing policies and the high cost of drug development threaten the global leadership of the U.S. biopharma industry. The op-ed calls on policymakers to take actions that would support further innovation in biopharma. Item

Suggested Articles

Gilead is considering repositioning NUC inhibitor remdesivir as a treatment for the coronavirus now sweeping across parts of China.

Ipsen has paused a phase 3 trial of palovarotene after an interim analysis found it is unlikely to meet its primary efficacy endpoint.

Scientists at the Broad Institute and the Dana-Farber Cancer Institute identified 49 existing drugs they believe could be repurposed to treat cancer.